Retinal Vein Occlusion News and Research

RSS

Central retinal vein occlusion (CRVO) is the most common disease of the retinal vessels. It refers to a blockage of the vein draining the retinal tissue at the back of the eye. Occurring mostly in the elderly or middle-aged, it causes a subacute loss of vision.

AI-Doctor's accuracy in retinal disease detection redefines medical diagnosis

An advanced artificial Intelligence (AI) system designed to interpret fundus fluorescein angiography (FFA) images precisely.

25 Sep 2023

The role of diet in the management of retinal vein occlusion

Researchers investigate the potential impact of dietary habits on retinal vein occlusion.

27 Jul 2023

UVA research provides new insight into common causes of vision loss

UVA Health scientists have discovered an unknown contributor to harmful blood vessel growth in the eye that could lead to new treatments for blinding macular degeneration and other common causes of vision loss.

24 Feb 2023

Topical ocular administration of progesterone could be viable treatment for retinitis pigmentosa

Retinitis pigmentosa is a degenerative disease affecting the photoreceptor cells in the retina, known as cones and rods.

30 May 2022

Treatment for retinal vein occlusion yields long-lasting vision gains, study shows

New research shows that a treatment for retinal vein occlusion yields long-lasting vision gains, with visual acuity remaining significantly above baseline at five years.

21 Apr 2022

COVID-19 patients' eyes and tears can be infected with SARS-CoV-2

A new study investigates the presence of SARS-CoV-2 in tears and eye secretions and describes the ocular symptoms in patients with COVID-19.

31 Oct 2021

AI could predict treatment demand for chronic eye diseases

Age-related macular degeneration (AMD) is the most common cause of vision loss in people over 50. Up to 12 percent of those over 80 have the chronic disease.

8 Jun 2021

New mobile app can help people diagnosed with glaucoma

Researchers from City, University London, supported by Allergan Pharmaceuticals and Glaucoma UK, have today released the latest edition of an app to help people newly diagnosed with glaucoma.

8 Mar 2021

New eye drops could prevent vision loss after retinal vein occlusion

Researchers at Columbia University Irving Medical Center have developed eye drops that could prevent vision loss after retinal vein occlusion, a major cause of blindness for millions of adults worldwide.

29 Jun 2020

RetiPharma secures funding to develop new peptide drug for treating degenerative eye disorders

RetiPharma has secured funding from the Novo Nordisk Foundation’s BioInnovation Institute to develop a new drug for degenerative eye disorders.

From Novo Nordisk 15 Nov 2018

Gilead Sciences presents Phase 3 results of filgotinib in biologic-experienced rheumatoid arthritis at 2018 ACR/ARHP Annual Meeting

Gilead Sciences, Inc. and Galapagos NV today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents.

22 Oct 2018

Saving sight of millions by making eye injections safe and comfortable

Two eye surgeons have written a first-of-its-kind book to save the sight of millions of patients around the world by making eye injections safe and comfortable.

7 Aug 2018

FDA approves marketing of AI device to detect diabetic retinopathy

The U.S. Food and Drug Administration yesterday (11th of April 2018), released a statement approving the marketing of world’s first artificial intelligence using medical device that can detect diabetic retinopathy among diabetic patients.

12 Apr 2018

FDA authorizes marketing of first AI device to detect diabetic retinopathy

The U.S. Food and Drug Administration today permitted marketing of the first medical device to use artificial intelligence to detect greater than a mild level of the eye disease diabetic retinopathy in adults who have diabetes.

12 Apr 2018

Study suggests potential means of stalling or even reversing diabetes-related blindness

Johns Hopkins researchers have discovered a cell signaling pathway in mice that triggers vision loss in patients with diabetic retinopathy and retinal vein occlusion – diseases characterized by the closure of blood vessels in the retina, leading to blindness.

3 Jan 2018

Largest clinical specialty database powers studies that yield key insights

The American Academy of Ophthalmology today announced key milestones and clinical insights from studies powered by its clinical database.

13 Nov 2017

Two widely used drugs show effectiveness in treating patients with CRVO-associated macular edema

Monthly eye injections of Avastin (bevacizumab) are as effective as the more expensive drug Eylea (aflibercept) for the treatment of central retinal vein occlusion, according to a clinical trial funded by the National Eye Institute, part of the National Institutes of Health.

10 May 2017

Bayer Yakuhin receives MHLW approval in Japan for EYLEA (aflibercept) Injection to treat RVO patients

Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd., received approval for EYLEA (aflibercept) Injection by the Ministry of Health, Labour and Welfare (MHLW) in Japan for the treatment of patients with macular edema secondary to retinal vein occlusion (RVO).

26 Jun 2015

IQWiG examines added benefit of aflibercept in macular oedema after branch retinal vein occlusion

Since February 2015, aflibercept (trade name Eylea) has been available also for patients with impaired vision due to macular oedema that follows blockage of branch veins of the central retinal vein (branch retinal vein occlusion, BRVO).

24 Jun 2015

Bayer HealthCare, Johns Hopkins University to jointly develop new ophthalmic therapies targeting retinal diseases

The Johns Hopkins University and Bayer HealthCare have entered into a five-year collaboration agreement to jointly develop new ophthalmic therapies targeting retinal diseases. The goal of the strategic research alliance is to accelerate the translation of innovative approaches from the laboratory to the clinic, ultimately offering patients new treatment options for several retinal diseases.

17 Jun 2015